Clinical trials
Osteoarthritis, Knee trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2014 | 3 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Unknown status | 24 |
| Not yet recruiting | 4 |
| Recruiting | 4 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking University Third Hospital | 3 |
| Qilu Hospital of Shandong University | 3 |
| RenJi Hospital | 3 |
| Xiangya Hospital of Central South University | 3 |
| First Affiliated Hospital of Harbin Medical University | 2 |
| The Affiliated Hospital of Qingdao University | 2 |
| West China Hospital | 2 |
| Yantai Yuhuangding Hospital | 2 |
| Zhujiang Hospital | 2 |
| Anna Sun | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteoarthritis, Knee | 57 |
| Osteoarthritis | 4 |
| Pain | 4 |
| Postoperative Cognitive Complications | 2 |
| Anterior Cruciate Ligament Injuries | 1 |
| Arthritis | 1 |
| Cholecystitis | 1 |
| Coronary Artery Disease | 1 |
| Femoral Neck Fractures | 1 |
| Femur Head Necrosis | 1 |
Trials
Showing 1 to 25 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.